HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 BlockadeAleix Prat, Mothaffar F. Rimawi, Ian E. Krop et al.|JNCI Journal of the National Cancer Institute|2019Cited by 168
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockadeFara Brasó‐Maristany, Aleix Prat|Nature Communications|2020Cited by 118
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluationAleix Prat, PierFranco Conte, Valentina Guarneri et al.|The Lancet Oncology|2020Cited by 75
HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trialValentina Guarneri, Aleix Prat, Fara Brasó‐Maristany et al.|EBioMedicine|2022Cited by 42
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1Fara Brasó‐Maristany, Valentina Guarneri, Gaia Griguolo et al.|JNCI Journal of the National Cancer Institute|2022Cited by 25